Short-term impact of surgically induced menopause on cognitive function and wellbeing in women at high risk for ovarian cancer following risk-reducing bilateral salpingo-oophorectomy.
Journal
Menopause (New York, N.Y.)
ISSN: 1530-0374
Titre abrégé: Menopause
Pays: United States
ID NLM: 9433353
Informations de publication
Date de publication:
21 12 2020
21 12 2020
Historique:
pubmed:
23
12
2020
medline:
28
4
2021
entrez:
22
12
2020
Statut:
epublish
Résumé
Risk-reducing bilateral salpingo-oophorectomy (RRSO) is an effective strategy to prevent pelvic serous carcinoma for women at high risk of developing ovarian cancer; however, it results in premature menopause. Data is lacking to adequately counsel these women about potential effects of premature menopause on cognition and quality of life. A prospective study in premenopausal women at high risk of ovarian cancer to determine changes in cognition over time after RRSO and the impact of hormone therapy (HT) on cognition. Participants were surveyed before and after surgery using the Functional Assessment of Cancer Therapy-Cognitive questionnaire and questions regarding domains of wellbeing at 6, 12 and 18 months. Data was tested for changes across time using mixed model regression and logistic regression. Fifty-seven women were included. Sixty-three percent of participants used HT. At 6 months postoperatively, perceived cognitive impairment declined by 5.5 points overall (4.4 in non-HT users and 6 in HT users), P = 0.003. The other domains of cognition assessed did not change significantly over time and the use of HT did not impact scores. Sleep disruption was common in this cohort and was not mitigated by HT. Self-reported depression improved after RRSO (P = 0.004). Women at high risk of ovarian cancer who choose RRSO may experience declines in cognition within the first 6 months of surgical menopause. HT may cause small declines in perceived cognitive impairment at 6 months after RRSO. Women can expect more sleep disruption after menopause, which is not mitigated by HT. Video Summary:http://links.lww.com/MENO/A697.
Autres résumés
Type: plain-language-summary
(eng)
Video Summary:http://links.lww.com/MENO/A697.
Identifiants
pubmed: 33350669
doi: 10.1097/GME.0000000000001716
pii: 00042192-202104000-00004
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
354-359Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 by The North American Menopause Society.
Déclaration de conflit d'intérêts
Financial disclosure/conflicts of interest: None reported.
Références
Committee on Practice Bulletins–Gynecology, Committee on Genetics, Society of Gynecologic Oncology. Hereditary breast and ovarian cancer syndrome. Practice Bulletin No. 182. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017; 130:e110–e126.
NCCN guidelines: Genetic/Familial High-Risk Assessment: Breast and Ovarian Cancer. NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician-gls/pdf/genetics_screening.pdf Version 2. 2019-July 30, 2018. Accessed December 5, 2018.
Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause on considerations for management. Climacteric 2015; 13:483–491.
McEwan BS. Invited review: estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 2001; 91:2785–2801.
Greendale GA, Derby CA, Maki PM. Perimenopause and cognition. Obstet Gynecol Clin North Am 2011; 38:519–535.
Voss JL, Bridge DJ, Cohen NJ, Walker JA. A closer look at the hippocampus and memory. Trends Cogn Sci 2017; 21:577–588.
Miller EK. The prefrontal cortex and cognitive control. Nature Rev Neuroscience 2000; 1:59–65.
Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000; 152:463–473.
Sullivan ME, Woods F. Midlife women's attributions about perceived memory changes: observations from the Seattle midline women's health study. J Women's Health Gend Based Med 2001; 10:351–362.
Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007; 69:1074–1083.
Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive function in in surgically menopausal women. Psychoneuroendocrinology 1988; 13:345–357.
Farrag AF, Khedr EM, Abdel-Aleem H, Rageh RA. Effect of surgical menopause on cognitive functions. Dement Geriatr Cogn Disord 2002; 13:193–198.
LeBlanc ES, Neiss MB, Carello PE, Samuels MH, Janowsky JS. Hot flashes and estrogen therapy do not influence cognition in early menopausal women. Menopause 2007; 14:191–202.
Costa DSJ, Loh V, Birney DP, et al. The structure of the FACT-Cog v3 in cancer patients, students, and older adults. J Pain Symptom Manage 2018; 55:1173–1178.
Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22:2233–2239.
Vardy J, Wong K, Yi QL, et al. Assessing cognitive function in cancer patients. Support Care Cancer 2006; 14:1111–1118.
Bell ML, Dhillon HM, Bray VJ, Vardy JL. Important differences and meaningful changes for the functional assessment of cancer therapy-cognitive function (FACT-Cog). J Patient Rep Outcomes 2018; 2:48.
Van Dyk K, Crespi CM, Crespi Petersen L, Ganz PA. Identifying cancer-related cognitive impairment using the FACT-Cog perceived cognitive impairment. JNCI Cancer Spectrum 2020; 4:kz099.
Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992; 17:485–495.
Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289:2651–2662.
Espeland MA, Shumaker SA, Leng I, et al. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 2013; 173:1429–1436.
Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS–Cognitive and Affective Study. PLoS Med 2015; 12:e1001833.
Morgan KN, Derby CA, Gleason CE. Cognitive changes with reproductive aging, perimenopause, and menopause. Obstet Gynecol Clin 2018; 45:751–763.
Michelsen TM, Dørum A, Dahl AA. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk of hereditary breast ovarian cancer. Gynecol Oncol 2009; 113:128–133.
Neggen DR, Hurteau J, Holman LL, et al. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: a pilot study in women with BRCA1/2 mutations. Gynecol Oncol 2018; 150:79–84.
Steenbeek MP, Harmsen MG, Hermens RPMG, de Hullu JA. D. TUBA group. Worry and regret in the prospective multicenter TUBA study in BRCA1/2 mutation carriers. Gynecol Oncol 2019; 154:22.
Hall E, Finch A, Jacobson M, et al. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with BRCA1 or BRCA2 mutations. Gynecol Oncol 2019; 152:145–150.
Vermeulen RFM, van Beurden M, Korse CM, Kenter GG. Impact of risk-reducing salpingo-oophorectomy in premenopausal women. Climacteric 2017; 20:212–221.
Finch A, Evans G, Narod SA. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond) 2012;8:543–555.
Gordhandas S, Norquist BM, Pennington KP, et al. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations: a systematic review of risks and benefits. Gynecol Oncol 2019; 153:192–200.
Mashochak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharamcodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1992; 144:511.